Cationic drugs and COVID-19

Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic group...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenna, Oreste Vittore, Torretta, Sara, Pignataro, Lorenzo, Di Berardino, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557649/
https://www.ncbi.nlm.nih.gov/pubmed/33045858
http://dx.doi.org/10.1177/2058738420966078
_version_ 1783594468031594496
author Brenna, Oreste Vittore
Torretta, Sara
Pignataro, Lorenzo
Di Berardino, Federica
author_facet Brenna, Oreste Vittore
Torretta, Sara
Pignataro, Lorenzo
Di Berardino, Federica
author_sort Brenna, Oreste Vittore
collection PubMed
description Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic groups) could have any effect in impairing SARS-CoV2 entry in the host cell. This could open to new therapeutic chances against COVID-19.
format Online
Article
Text
id pubmed-7557649
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75576492020-10-26 Cationic drugs and COVID-19 Brenna, Oreste Vittore Torretta, Sara Pignataro, Lorenzo Di Berardino, Federica Int J Immunopathol Pharmacol Letter to the Editor Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic groups) could have any effect in impairing SARS-CoV2 entry in the host cell. This could open to new therapeutic chances against COVID-19. SAGE Publications 2020-10-13 /pmc/articles/PMC7557649/ /pubmed/33045858 http://dx.doi.org/10.1177/2058738420966078 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Letter to the Editor
Brenna, Oreste Vittore
Torretta, Sara
Pignataro, Lorenzo
Di Berardino, Federica
Cationic drugs and COVID-19
title Cationic drugs and COVID-19
title_full Cationic drugs and COVID-19
title_fullStr Cationic drugs and COVID-19
title_full_unstemmed Cationic drugs and COVID-19
title_short Cationic drugs and COVID-19
title_sort cationic drugs and covid-19
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557649/
https://www.ncbi.nlm.nih.gov/pubmed/33045858
http://dx.doi.org/10.1177/2058738420966078
work_keys_str_mv AT brennaorestevittore cationicdrugsandcovid19
AT torrettasara cationicdrugsandcovid19
AT pignatarolorenzo cationicdrugsandcovid19
AT diberardinofederica cationicdrugsandcovid19

Ejemplares similares